CG Oncology, Inc. Common stock

CGONNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
71.85 USD
↗ 2.35 (3.38%)AT CLOSE (11:59 AM EDT)
71.87
↗ 0.02 (0.03%)
POST MARKET (AS OF 04:48 PM EDT)
Post Market
AS OF 04:48 PM EDT
71.87
↗ 0.02 (0.03%)
🟢Market: OPEN

CGON is currently priced at $72.98. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, CGON trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jul 17, 2026.

Open?$68.72
High?$72.92
Low?$68.72
Prev. Close?$69.50
Volume?1.1M
Avg. Volume?1.2M
VWAP?$72.16
Rel. Volume?0.89x
Bid / Ask
Bid?$58.96 × 100
Ask?$86.96 × 100
Spread?$28.00
Midpoint?$72.96
Valuation & Ratios
Market Cap?6.1B
Shares Out?88.2M
Float?55.6M
Float %?68.9%
P/E Ratio?N/A
P/B Ratio?5.61
EPS?-$2.12
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
142
Market Cap
6.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cgoncology.com
Listed
2024-01-25
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Phone: (949) 409-3700
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
100
Momentum?
18
Short Sent.?
20
Piotroski F-Score?2/9Weak
Altman Z-Score?84.55Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.70%Squeeze Risk
Short Interest?12.1M
Days to Cover?7.6
Free Float55.6M
Avg Daily Volume1.6M
Settlement Date2026-06-30
Financial Health
Current Ratio?31.30Strong
Quick Ratio?31.25Strong
Cash Ratio?0.96Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
33
5.61FAIR▾
P/S?
Peers
100
S&P
3
1,208.85HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-28.7CHEAP▾
EV/Sales?
Peers
100
S&P
3
1,202.79HIGH▾
Returns & Efficiency
ROE?
S&P
8
-17.1%WEAK▾
ROA?
S&P
3
-16.5%WEAK▾
Cash Flow & Enterprise
FCF?$-160434000
Enterprise Value?$6.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist